Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Working Capital Changes (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Other Working Capital Changes for 5 consecutive years, with -$16.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 611.14% year-over-year to -$16.2 million, compared with a TTM value of -$3.5 million through Dec 2025, down 9771.43%, and an annual FY2025 reading of -$3.5 million, down 9771.43% over the prior year.
  • Other Working Capital Changes was -$16.2 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $507000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $14.3 million in Q3 2022 and bottomed at -$24.7 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is $110250.0, with a median of -$188000.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes soared 1949.11% in 2022, then plummeted 8433.33% in 2024.
  • Year by year, Other Working Capital Changes stood at -$1.9 million in 2021, then plummeted by 1196.33% to -$24.7 million in 2022, then skyrocketed by 64.22% to -$8.8 million in 2023, then soared by 135.74% to $3.2 million in 2024, then tumbled by 611.14% to -$16.2 million in 2025.
  • Business Quant data shows Other Working Capital Changes for KNSA at -$16.2 million in Q4 2025, $507000.0 in Q3 2025, and $13.0 million in Q2 2025.